| Compound | BPC-157 + GHK-Cu + TB-500 + KPV |
|---|---|
| Category | Vendor blend (healing peptides) |
| Class | Healing and Anti-Inflammatory Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
BPC-157 + GHK-Cu + TB-500 + KPV — a vendor blend (healing peptides) — sits in the "Minimal evidence" tier of this catalog. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A four-component vendor blend adding the anti-inflammatory tripeptide KPV to the BPC-157/GHK-Cu/TB-500 stack. As with other blends, the combination is unsupported by any published trial.
Mechanism of Action
The stated rationale stacks four mechanistic hypotheses — tissue repair, copper-peptide biology, thymosin activity, and inflammation modulation — without evidence that they combine beneficially.
Research and Evidence
No clinical or preclinical study of this four-way combination has been published.
Safety and Side Effects
The more ingredients in an unregulated blend, the more uncharacterized the risk; sterility and identity verification are the immediate concerns.
Frequently Asked Questions
What is the evidence tier of BPC-157 + GHK-Cu + TB-500 + KPV?
BPC-157 + GHK-Cu + TB-500 + KPV is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is BPC-157 + GHK-Cu + TB-500 + KPV an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for BPC-157 + GHK-Cu + TB-500 + KPV?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — no combination trials registered. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.